Literature DB >> 20463344

Whistle-blowers' experiences in fraud litigation against pharmaceutical companies.

Aaron S Kesselheim1, David M Studdert, Michelle M Mello.   

Abstract

Mesh：

Year:  2010        PMID： 20463344     DOI： 10.1056/NEJMsr0912039

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Embedding 'speaking up' into systems for safe healthcare product development and marketing surveillance.

Authors:  Brian Edwards; Bruce Hugman; Mary Tobin; Matthew Whalen
Journal:  Drug Saf       Date:  2012-04-01       Impact factor: 5.606

2.  Off-label use of atypical antipsychotics: cause for concern?

Authors:  Andrew McKean; Erik Monasterio
Journal:  CNS Drugs       Date:  2012-05-01       Impact factor: 5.749

3.  Why Not Blow the Whistle on Health Care Insurance Fraud? Evidence from Jiangsu Province, China.

Authors:  Dandan Wang; Changchun Zhan
Journal:  Risk Manag Healthc Policy       Date:  2022-10-12

4.  Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints.

Authors:  Aaron S Kesselheim; Michelle M Mello; David M Studdert
Journal:  PLoS Med       Date:  2011-04-05       Impact factor: 11.069

Review 5.  A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in Japan.

Authors:  Tetsuya Tanimoto
Journal:  Drug Des Devel Ther       Date:  2015-03-31       Impact factor: 4.162

6.  Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.

Authors:  Andreas Vilhelmsson; Courtney Davis; Shai Mulinari
Journal:  PLoS Med       Date:  2016-01-26       Impact factor: 11.069
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.